The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis
Objective To evaluate the impact of pre‐intensive care unit admission (pre‐ICU) statin use on all‐cause in‐hospital mortality and ICU length of stay (LOS). Design Retrospective cohort study. Setting Adult ICUs at tertiary hospitals. Patients Adult critically ill patients diagnosed with sepsis admitt...
Gespeichert in:
Veröffentlicht in: | Pharmacotherapy 2021-02, Vol.41 (2), p.162-171 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 171 |
---|---|
container_issue | 2 |
container_start_page | 162 |
container_title | Pharmacotherapy |
container_volume | 41 |
creator | Chinaeke, Eric E. Love, Bryan L. Magagnoli, Joe Yunusa, Ismaeel Reeder, Gene |
description | Objective
To evaluate the impact of pre‐intensive care unit admission (pre‐ICU) statin use on all‐cause in‐hospital mortality and ICU length of stay (LOS).
Design
Retrospective cohort study.
Setting
Adult ICUs at tertiary hospitals.
Patients
Adult critically ill patients diagnosed with sepsis admitted to the ICUs.
Intervention
The exposure was pre‐ICU statin prescription (statin users); unexposed represented absence of pre‐ICU prescription (non‐users).
Measurement and Main Results
We used the 2001–2012 Medical Information Mart for Intensive Care‐III (MIMIC‐III) database to determine average treatment effect (ATE) of pre‐ICU statin use on 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality using the Augmented Inverse Propensity Weighted technique (AIPW), after adjusting for confounding factors (age, race, health insurance, corticosteroids use, vital signs, laboratory tests, and Sequential Organ Failure Assessment score (SOFA). We measured 30‐day ICU mortality as deaths within 30 days of admission to the ICU, and ICU LOS was measured in fractional days. A 30‐day in‐hospital mortality was measured as death within 30 days of hospital admission. A total of 8200 patients with sepsis were identified; 19.8% (1623) were statin users, and 80.2% (6577) were non‐users. Most were Caucasian, aged 80 years and above, and male. After adjusting for confounding factors, pre‐ICU statin use decreased 30‐day ICU mortality (ATE, −0.026; 95% confidence interval [CI], −0.048 to −0.009); ICU LOS (ATE, −0.369; 95% Cl, −0.849 to −0.096); and 30‐day in‐hospital mortality (ATE, −0.039; 95% CI, −0.084 to −0.026) on average compared with non‐statin use, respectively. In a stratified analysis, the result for ICU LOS (ATE, −0.526; 95% CI, −0.879 to −0.241) and 30‐day in‐hospital mortality (ATE, −0.023; 95% CI, −0.048 to −0.002) was consistent among patients admitted to the medical ICU.
Conclusions
Among patients with sepsis admitted to the medical ICU, pre‐ICU statin use is causally associated with a decrease in 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality compared to non‐use. This study adds to the totality of evidence on the pleiotropic effect of statin use in patients with sepsis. |
doi_str_mv | 10.1002/phar.2506 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7920641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2492250400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-84f938636b61b57e2ad7be025a38dd9939c162725365a1f557d36c5efa2ed493</originalsourceid><addsrcrecordid>eNp1kV1rFDEYhYModq1e-Ack4E29mDbfmbkRSlErFBTZ-5DNvOOmZJMxybTsvzfr1qKCEHgv8vBwDgeh15ScU0LYxby1-ZxJop6gFe217AZKxVO0IkzrjhDSn6AXpdw2lCrBnqMTzkVPmR5WaFpvAfvdbF3FacKl2uojXgrgOfuUcU3Yxwqx-DvAzmbAS_QV23HnS_Ep4vZc9tU7G8Ie-xDw3BQQa8H3vm5xgbn48hI9m2wo8OrhnqL1xw_rq-vu5sunz1eXN50TgquuF9PAe8XVRtGN1MDsqDdAmLS8H8dh4IOjimkmuZKWTlLqkSsnYbIMRjHwU_T-qJ2XzQ5G12JkG0yrsrN5b5L15u-f6Lfme7ozemBECdoEZw-CnH4sUKppPR2EYCOkpRgmesKp4qxv6Nt_0Nu05NjaNWpgbQ5BSKPeHSmXUykZpscwlJjDeOYwnjmM19g3f6Z_JH-v1YCLI3DvA-z_bzJfry-__VL-BAQEpVE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2492250400</pqid></control><display><type>article</type><title>The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chinaeke, Eric E. ; Love, Bryan L. ; Magagnoli, Joe ; Yunusa, Ismaeel ; Reeder, Gene</creator><creatorcontrib>Chinaeke, Eric E. ; Love, Bryan L. ; Magagnoli, Joe ; Yunusa, Ismaeel ; Reeder, Gene</creatorcontrib><description>Objective
To evaluate the impact of pre‐intensive care unit admission (pre‐ICU) statin use on all‐cause in‐hospital mortality and ICU length of stay (LOS).
Design
Retrospective cohort study.
Setting
Adult ICUs at tertiary hospitals.
Patients
Adult critically ill patients diagnosed with sepsis admitted to the ICUs.
Intervention
The exposure was pre‐ICU statin prescription (statin users); unexposed represented absence of pre‐ICU prescription (non‐users).
Measurement and Main Results
We used the 2001–2012 Medical Information Mart for Intensive Care‐III (MIMIC‐III) database to determine average treatment effect (ATE) of pre‐ICU statin use on 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality using the Augmented Inverse Propensity Weighted technique (AIPW), after adjusting for confounding factors (age, race, health insurance, corticosteroids use, vital signs, laboratory tests, and Sequential Organ Failure Assessment score (SOFA). We measured 30‐day ICU mortality as deaths within 30 days of admission to the ICU, and ICU LOS was measured in fractional days. A 30‐day in‐hospital mortality was measured as death within 30 days of hospital admission. A total of 8200 patients with sepsis were identified; 19.8% (1623) were statin users, and 80.2% (6577) were non‐users. Most were Caucasian, aged 80 years and above, and male. After adjusting for confounding factors, pre‐ICU statin use decreased 30‐day ICU mortality (ATE, −0.026; 95% confidence interval [CI], −0.048 to −0.009); ICU LOS (ATE, −0.369; 95% Cl, −0.849 to −0.096); and 30‐day in‐hospital mortality (ATE, −0.039; 95% CI, −0.084 to −0.026) on average compared with non‐statin use, respectively. In a stratified analysis, the result for ICU LOS (ATE, −0.526; 95% CI, −0.879 to −0.241) and 30‐day in‐hospital mortality (ATE, −0.023; 95% CI, −0.048 to −0.002) was consistent among patients admitted to the medical ICU.
Conclusions
Among patients with sepsis admitted to the medical ICU, pre‐ICU statin use is causally associated with a decrease in 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality compared to non‐use. This study adds to the totality of evidence on the pleiotropic effect of statin use in patients with sepsis.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1002/phar.2506</identifier><identifier>PMID: 33481279</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged, 80 and over ; Corticosteroids ; critical care ; Critical Illness ; Hospital Mortality ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; hydroxymethylglutaryl‐CoA reductase inhibitors ; Intensive care ; Intensive Care Units ; Length of Stay ; Male ; Mortality ; organ dysfunction scores ; Patients ; Retrospective Studies ; Sepsis ; Sepsis - drug therapy ; septic shock</subject><ispartof>Pharmacotherapy, 2021-02, Vol.41 (2), p.162-171</ispartof><rights>2021 Pharmacotherapy Publications, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-84f938636b61b57e2ad7be025a38dd9939c162725365a1f557d36c5efa2ed493</citedby><cites>FETCH-LOGICAL-c4436-84f938636b61b57e2ad7be025a38dd9939c162725365a1f557d36c5efa2ed493</cites><orcidid>0000-0002-8568-0097 ; 0000-0002-8287-0012 ; 0000-0002-9221-9143 ; 0000-0002-9107-8561</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fphar.2506$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fphar.2506$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33481279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chinaeke, Eric E.</creatorcontrib><creatorcontrib>Love, Bryan L.</creatorcontrib><creatorcontrib>Magagnoli, Joe</creatorcontrib><creatorcontrib>Yunusa, Ismaeel</creatorcontrib><creatorcontrib>Reeder, Gene</creatorcontrib><title>The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Objective
To evaluate the impact of pre‐intensive care unit admission (pre‐ICU) statin use on all‐cause in‐hospital mortality and ICU length of stay (LOS).
Design
Retrospective cohort study.
Setting
Adult ICUs at tertiary hospitals.
Patients
Adult critically ill patients diagnosed with sepsis admitted to the ICUs.
Intervention
The exposure was pre‐ICU statin prescription (statin users); unexposed represented absence of pre‐ICU prescription (non‐users).
Measurement and Main Results
We used the 2001–2012 Medical Information Mart for Intensive Care‐III (MIMIC‐III) database to determine average treatment effect (ATE) of pre‐ICU statin use on 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality using the Augmented Inverse Propensity Weighted technique (AIPW), after adjusting for confounding factors (age, race, health insurance, corticosteroids use, vital signs, laboratory tests, and Sequential Organ Failure Assessment score (SOFA). We measured 30‐day ICU mortality as deaths within 30 days of admission to the ICU, and ICU LOS was measured in fractional days. A 30‐day in‐hospital mortality was measured as death within 30 days of hospital admission. A total of 8200 patients with sepsis were identified; 19.8% (1623) were statin users, and 80.2% (6577) were non‐users. Most were Caucasian, aged 80 years and above, and male. After adjusting for confounding factors, pre‐ICU statin use decreased 30‐day ICU mortality (ATE, −0.026; 95% confidence interval [CI], −0.048 to −0.009); ICU LOS (ATE, −0.369; 95% Cl, −0.849 to −0.096); and 30‐day in‐hospital mortality (ATE, −0.039; 95% CI, −0.084 to −0.026) on average compared with non‐statin use, respectively. In a stratified analysis, the result for ICU LOS (ATE, −0.526; 95% CI, −0.879 to −0.241) and 30‐day in‐hospital mortality (ATE, −0.023; 95% CI, −0.048 to −0.002) was consistent among patients admitted to the medical ICU.
Conclusions
Among patients with sepsis admitted to the medical ICU, pre‐ICU statin use is causally associated with a decrease in 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality compared to non‐use. This study adds to the totality of evidence on the pleiotropic effect of statin use in patients with sepsis.</description><subject>Adult</subject><subject>Aged, 80 and over</subject><subject>Corticosteroids</subject><subject>critical care</subject><subject>Critical Illness</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>hydroxymethylglutaryl‐CoA reductase inhibitors</subject><subject>Intensive care</subject><subject>Intensive Care Units</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Mortality</subject><subject>organ dysfunction scores</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Sepsis</subject><subject>Sepsis - drug therapy</subject><subject>septic shock</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1rFDEYhYModq1e-Ack4E29mDbfmbkRSlErFBTZ-5DNvOOmZJMxybTsvzfr1qKCEHgv8vBwDgeh15ScU0LYxby1-ZxJop6gFe217AZKxVO0IkzrjhDSn6AXpdw2lCrBnqMTzkVPmR5WaFpvAfvdbF3FacKl2uojXgrgOfuUcU3Yxwqx-DvAzmbAS_QV23HnS_Ep4vZc9tU7G8Ie-xDw3BQQa8H3vm5xgbn48hI9m2wo8OrhnqL1xw_rq-vu5sunz1eXN50TgquuF9PAe8XVRtGN1MDsqDdAmLS8H8dh4IOjimkmuZKWTlLqkSsnYbIMRjHwU_T-qJ2XzQ5G12JkG0yrsrN5b5L15u-f6Lfme7ozemBECdoEZw-CnH4sUKppPR2EYCOkpRgmesKp4qxv6Nt_0Nu05NjaNWpgbQ5BSKPeHSmXUykZpscwlJjDeOYwnjmM19g3f6Z_JH-v1YCLI3DvA-z_bzJfry-__VL-BAQEpVE</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Chinaeke, Eric E.</creator><creator>Love, Bryan L.</creator><creator>Magagnoli, Joe</creator><creator>Yunusa, Ismaeel</creator><creator>Reeder, Gene</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8568-0097</orcidid><orcidid>https://orcid.org/0000-0002-8287-0012</orcidid><orcidid>https://orcid.org/0000-0002-9221-9143</orcidid><orcidid>https://orcid.org/0000-0002-9107-8561</orcidid></search><sort><creationdate>202102</creationdate><title>The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis</title><author>Chinaeke, Eric E. ; Love, Bryan L. ; Magagnoli, Joe ; Yunusa, Ismaeel ; Reeder, Gene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-84f938636b61b57e2ad7be025a38dd9939c162725365a1f557d36c5efa2ed493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged, 80 and over</topic><topic>Corticosteroids</topic><topic>critical care</topic><topic>Critical Illness</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>hydroxymethylglutaryl‐CoA reductase inhibitors</topic><topic>Intensive care</topic><topic>Intensive Care Units</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Mortality</topic><topic>organ dysfunction scores</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Sepsis</topic><topic>Sepsis - drug therapy</topic><topic>septic shock</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chinaeke, Eric E.</creatorcontrib><creatorcontrib>Love, Bryan L.</creatorcontrib><creatorcontrib>Magagnoli, Joe</creatorcontrib><creatorcontrib>Yunusa, Ismaeel</creatorcontrib><creatorcontrib>Reeder, Gene</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chinaeke, Eric E.</au><au>Love, Bryan L.</au><au>Magagnoli, Joe</au><au>Yunusa, Ismaeel</au><au>Reeder, Gene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2021-02</date><risdate>2021</risdate><volume>41</volume><issue>2</issue><spage>162</spage><epage>171</epage><pages>162-171</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><abstract>Objective
To evaluate the impact of pre‐intensive care unit admission (pre‐ICU) statin use on all‐cause in‐hospital mortality and ICU length of stay (LOS).
Design
Retrospective cohort study.
Setting
Adult ICUs at tertiary hospitals.
Patients
Adult critically ill patients diagnosed with sepsis admitted to the ICUs.
Intervention
The exposure was pre‐ICU statin prescription (statin users); unexposed represented absence of pre‐ICU prescription (non‐users).
Measurement and Main Results
We used the 2001–2012 Medical Information Mart for Intensive Care‐III (MIMIC‐III) database to determine average treatment effect (ATE) of pre‐ICU statin use on 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality using the Augmented Inverse Propensity Weighted technique (AIPW), after adjusting for confounding factors (age, race, health insurance, corticosteroids use, vital signs, laboratory tests, and Sequential Organ Failure Assessment score (SOFA). We measured 30‐day ICU mortality as deaths within 30 days of admission to the ICU, and ICU LOS was measured in fractional days. A 30‐day in‐hospital mortality was measured as death within 30 days of hospital admission. A total of 8200 patients with sepsis were identified; 19.8% (1623) were statin users, and 80.2% (6577) were non‐users. Most were Caucasian, aged 80 years and above, and male. After adjusting for confounding factors, pre‐ICU statin use decreased 30‐day ICU mortality (ATE, −0.026; 95% confidence interval [CI], −0.048 to −0.009); ICU LOS (ATE, −0.369; 95% Cl, −0.849 to −0.096); and 30‐day in‐hospital mortality (ATE, −0.039; 95% CI, −0.084 to −0.026) on average compared with non‐statin use, respectively. In a stratified analysis, the result for ICU LOS (ATE, −0.526; 95% CI, −0.879 to −0.241) and 30‐day in‐hospital mortality (ATE, −0.023; 95% CI, −0.048 to −0.002) was consistent among patients admitted to the medical ICU.
Conclusions
Among patients with sepsis admitted to the medical ICU, pre‐ICU statin use is causally associated with a decrease in 30‐day ICU mortality, ICU LOS, and 30‐day in‐hospital mortality compared to non‐use. This study adds to the totality of evidence on the pleiotropic effect of statin use in patients with sepsis.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33481279</pmid><doi>10.1002/phar.2506</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8568-0097</orcidid><orcidid>https://orcid.org/0000-0002-8287-0012</orcidid><orcidid>https://orcid.org/0000-0002-9221-9143</orcidid><orcidid>https://orcid.org/0000-0002-9107-8561</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0277-0008 |
ispartof | Pharmacotherapy, 2021-02, Vol.41 (2), p.162-171 |
issn | 0277-0008 1875-9114 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7920641 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adult Aged, 80 and over Corticosteroids critical care Critical Illness Hospital Mortality Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use hydroxymethylglutaryl‐CoA reductase inhibitors Intensive care Intensive Care Units Length of Stay Male Mortality organ dysfunction scores Patients Retrospective Studies Sepsis Sepsis - drug therapy septic shock |
title | The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20statin%20use%20prior%20to%20intensive%20care%20unit%20admission%20on%20critically%20ill%20patients%20with%20sepsis&rft.jtitle=Pharmacotherapy&rft.au=Chinaeke,%20Eric%20E.&rft.date=2021-02&rft.volume=41&rft.issue=2&rft.spage=162&rft.epage=171&rft.pages=162-171&rft.issn=0277-0008&rft.eissn=1875-9114&rft_id=info:doi/10.1002/phar.2506&rft_dat=%3Cproquest_pubme%3E2492250400%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2492250400&rft_id=info:pmid/33481279&rfr_iscdi=true |